Kiniksa Pharmaceuticals KNSA Stock
Kiniksa Pharmaceuticals Price Chart
Kiniksa Pharmaceuticals KNSA Financial and Trading Overview
| Kiniksa Pharmaceuticals stock price | 17.29 USD |
| Previous Close | 16.48 USD |
| Open | 16.5 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1200 |
| Day's Range | 16.33 - 16.82 USD |
| 52 Week Range | 8.14 - 17.2 USD |
| Volume | 594.86K USD |
| Avg. Volume | 410.61K USD |
| Market Cap | 1.14B USD |
| Beta (5Y Monthly) | -0.117605 |
| PE Ratio (TTM) | 5.72028 |
| EPS (TTM) | 0.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.25 USD |
KNSA Valuation Measures
| Enterprise Value | 970.06M USD |
| Trailing P/E | 5.72028 |
| Forward P/E | 1636.0001 |
| PEG Ratio (5 yr expected) | 0.24 |
| Price/Sales (ttm) | 4.838687 |
| Price/Book (mrq) | 2.9287505 |
| Enterprise Value/Revenue | 4.105 |
| Enterprise Value/EBITDA | 40.022 |
Trading Information
Kiniksa Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.117605 |
| 52-Week Change | 79.38% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.2 USD |
| 52 Week Low | 8.14 USD |
| 50-Day Moving Average | 13.14 USD |
| 200-Day Moving Average | 13.36 USD |
KNSA Share Statistics
| Avg. Volume (3 month) | 410.61K USD |
| Avg. Daily Volume (10-Days) | 412.63K USD |
| Shares Outstanding | 34.97M |
| Float | 29.39M |
| Short Ratio | 5.63 |
| % Held by Insiders | 3.85% |
| % Held by Institutions | 93.11% |
| Shares Short | 2.65M |
| Short % of Float | 8.41% |
| Short % of Shares Outstanding | 3.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 83.06% |
| Operating Margin (ttm) | 9.26% |
| Gross Margin | 78.92% |
| EBITDA Margin | 10.25% |
Management Effectiveness
| Return on Assets (ttm) | 4.06% |
| Return on Equity (ttm) | 70.56% |
Income Statement
| Revenue (ttm) | 236.34M USD |
| Revenue Per Share (ttm) | 3.4 USD |
| Quarterly Revenue Growth (yoy) | 50.20% |
| Gross Profit (ttm) | 173.21M USD |
| EBITDA | 24.24M USD |
| Net Income Avi to Common (ttm) | 196.3M USD |
| Diluted EPS (ttm) | 2.86 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 187.49M USD |
| Total Cash Per Share (mrq) | 2.68 USD |
| Total Debt (mrq) | 5.62M USD |
| Total Debt/Equity (mrq) | 1.44 USD |
| Current Ratio (mrq) | 6.327 |
| Book Value Per Share (mrq) | 5.586 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 38.39M USD |
| Levered Free Cash Flow (ttm) | 36.34M USD |
Profile of Kiniksa Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Hamilton |
| Address | Clarendon House |
| ZIP | HM 11 |
| Phone | N/A |
| Website | https://www.kiniksa.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 220 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Q&A For Kiniksa Pharmaceuticals Stock
What is a current KNSA stock price?
Kiniksa Pharmaceuticals KNSA stock price today per share is 17.29 USD.
How to purchase Kiniksa Pharmaceuticals stock?
You can buy KNSA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kiniksa Pharmaceuticals?
The stock symbol or ticker of Kiniksa Pharmaceuticals is KNSA.
Which industry does the Kiniksa Pharmaceuticals company belong to?
The Kiniksa Pharmaceuticals industry is Biotechnology.
How many shares does Kiniksa Pharmaceuticals have in circulation?
The max supply of Kiniksa Pharmaceuticals shares is 70.62M.
What is Kiniksa Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Kiniksa Pharmaceuticals PE Ratio is 86.45000500 now.
What was Kiniksa Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Kiniksa Pharmaceuticals EPS is 0.2 USD over the trailing 12 months.
Which sector does the Kiniksa Pharmaceuticals company belong to?
The Kiniksa Pharmaceuticals sector is Healthcare.
Kiniksa Pharmaceuticals KNSA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}